<DOC>
	<DOCNO>NCT00677807</DOCNO>
	<brief_summary>This study evaluate 1 year safety , tolerability efficacy indacaterol placebo treatment Chronic Obstructive Pulmonary Disease ( COPD ) patient</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Indacaterol Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Patients eligible participate study extension , definition , meet inclusion exclusion criterion core 26 week meet withdrawal criterion core study B2335S Visit 14 ( last visit core study B2335S first visit extension study B2335SE ) . In addition follow inclusion/exclusion criterion specify must meet . 1 . Patients must complete Stage 2 core study B2335S ( NCT00463567 ) . 2 . Written inform consent participate extension must obtain . 3 . Patients must able comply study requirement . Patients randomize openlabel tiotropium Study B2335S . Patients participate Stage 1 core study ( B2335S ) . Patients discontinue irrespective reason Stage 2 core study . Patients fail comply core protocol requirement procedure . Concomitant medical condition may interfere interpretation study result define core study protocol . Patients Investigator 's opinion participate extension study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>adult</keyword>
	<keyword>Î²2-agonist</keyword>
	<keyword>indacaterol</keyword>
</DOC>